Skip to main content
Addgene

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.

Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM, Lahdesmaki H, Rao A
Nat Commun. 2015 Jun 22;6:7307. doi: 10.1038/ncomms8307. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

ID Plasmid Purpose
74244pCMV6-XL4 ASXL1 (1-1304)Cancer-associated ASXL1 truncation mutant in mammalian expression vector
74245pCMV6-XL4 ASXL1 (p.G646 Wfs *12) 3x FLAGCancer-associated ASXL1 truncation mutant in mammalian expression vector
74261pCMV6-XL4 ASXL1 (p.Y591X) 3x FLAGCancer-associated ASXL1 truncation mutant in mammalian expression vector
74262pCMV6-XL4 ASXL1 (1-479) 3x FLAGCancer-associated ASXL1 truncation mutant in mammalian expression vector
74263pCMV6-XL4 ASXL1 (p.R404X) 3x FLAGCancer-associated ASXL1 truncation mutant in mammalian expression vector
81021MSCV-IRES-GFP ASXL1 (p.G646 Wfs *12) 3x FLAGCancer-associated ASXL1 truncation mutant in retroviral vector
81022MSCV-IRES-GFP ASXL1 (p.Y591X) 3x FLAGCancer-associated ASXL1 truncation mutant in retroviral vector
81023MSCV-IRES-GFP ASXL1 (1-479) 3x FLAGCancer-associated ASXL1 truncation mutant in retroviral vector
81024BAP1Retroviral vector containing human BAP1 and Thy1.1 selection marker
81025BAP1 C91ARetroviral vector containing human BAP1 C91A (catalytically inactive mutant) and Thy1.1 selection marker

Antibodies from Article